|
Re: "Actively Recruiting" ?
|
13
|
Resverlogix Corp.
|
Nov 09, 2021 03:41PM
|
|
Re: RVX 2023 valuation attempt using Moderna metrics
|
11
|
Resverlogix Corp.
|
Jan 30, 2022 12:28PM
|
|
Re: By the time….
|
10
|
Resverlogix Corp.
|
Mar 02, 2022 12:52PM
|
|
the silence of the mgmt indicates...
|
10
|
Resverlogix Corp.
|
Mar 19, 2021 05:49PM
|
|
Re: Those are some great stats, but unfortunately not ours.
|
9
|
Resverlogix Corp.
|
Jan 15, 2022 03:09PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
9
|
Resverlogix Corp.
|
Apr 06, 2022 08:48AM
|
|
CityNews cover
|
9
|
Resverlogix Corp.
|
Jan 31, 2022 09:20AM
|
|
Long COVID symptoms linked to inflammation
|
9
|
Resverlogix Corp.
|
Jun 28, 2022 06:06PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
8
|
Resverlogix Corp.
|
Apr 05, 2022 01:56PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
8
|
Resverlogix Corp.
|
Apr 05, 2022 06:04PM
|
|
COVID-19 treatment with RVX
|
8
|
Resverlogix Corp.
|
Apr 12, 2021 02:27PM
|
|
Re: Vaccines are here. That’s no reason to call off the hunt for effective COVID-19 treatments. Article from Market Watch...good read.
|
8
|
Resverlogix Corp.
|
Mar 19, 2021 08:22PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
7
|
Resverlogix Corp.
|
Apr 05, 2022 08:13PM
|
|
RVX's place in therapy - future prediction
|
7
|
Resverlogix Corp.
|
Mar 13, 2021 10:28AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
7
|
Resverlogix Corp.
|
Nov 29, 2021 11:31PM
|
|
Re: Vaccines are here. That’s no reason to call off the hunt for effective COVID-19 treatments. Article from Market Watch...good read.
|
7
|
Resverlogix Corp.
|
Mar 19, 2021 08:55PM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
6
|
Resverlogix Corp.
|
Nov 29, 2021 07:45PM
|
|
Re: Long Covid
|
6
|
Resverlogix Corp.
|
Jan 22, 2024 03:23PM
|
|
Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients
|
6
|
Resverlogix Corp.
|
Apr 05, 2022 12:07PM
|
|
Re: Here is the example of the danger of the COVID trial to RVX...
|
5
|
Resverlogix Corp.
|
Nov 11, 2021 01:22PM
|
